These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32989230)

  • 21. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
    Patki M; Huang Y; Ratnam M
    Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
    Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor splicing variant 7: Beyond being a constitutively active variant.
    Shao C; Yu B; Liu Y
    Life Sci; 2019 Oct; 234():116768. PubMed ID: 31445027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
    Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
    Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC.
    Erb HHH; Sparwasser P; Diehl T; Hemmerlein-Thomas M; Tsaur I; Jüngel E; Sommer U; Baretton GB; Haferkamp A; Neisius A; Thomas C
    Urol Int; 2020; 104(3-4):253-262. PubMed ID: 31955172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
    Lakshmana G; Baniahmad A
    Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
    Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
    Elife; 2023 Jan; 12():. PubMed ID: 36656639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer.
    Zhang Y; Ming A; Wang J; Chen W; Fang Z
    Pharmacol Res; 2024 Jul; 205():107234. PubMed ID: 38815882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
    Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
    Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
    Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.